Diabetes Treatment, Part 2: Oral Agents for Glycemic Management
Author:
- Michael J. FowlerMFMichael J. Fowler
- 1 October 2007
- journal article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 25 (4) , 131-134
Abstract
T he epidemic of type 2 diabetes in the United States and the rest of the world continues to grow rapidly; as many as 20 million people in the United States may have the disease.1 The vast majority of people with diabetes have type 2 diabetes, caused by a relative insulin deficiency superimposed on a background of insulin resistance.2 Most patients begin treatment with diet and exercise or incorporate them into their treatment regimen, but, unfortunately, most patients are unsuccessful in controlling type 2 diabetes through lifestyle modification alone and require pharmacotherapy. For several reasons, oral agents are typically the first medications used in the treatment of type 2 diabetes. Because of their wide range of efficacy, safety, and mechanisms of action, it is important for clinicians to gain a broad understanding of each class of oral agents to optimize diabetes control. This article reviews the major classes of oral agents used to treat type 2 diabetes, with an emphasis on the benefits and risks of each class. It is important to note that because type 1 diabetes results from an absolute deficiency of pancreatic β-cells, most oral agents are not indicated in the treatment of patients with type 1 diabetes. Oral agents are also largely not tested or approved for use in pregnancy. Metformin is the sole member of the biguanide class of medications in the United States. It replaced another biguanide, fenformin, which was removed from the market because of a propensity for lactic acidosis in 1975.3,4 Available in short-acting and sustained-release formulations, it is one of the oldest, and indeed one of the safest, medications used in the treatment of type 2 diabetes. Metformin exerts its effects primarily by decreasing hepatic glucose output and has a comparatively lesser effect increasing insulin sensitivity. …Keywords
This publication has 20 references indexed in Scilit:
- A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular EventsDiabetes Care, 2007
- Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsThe Journal of Clinical Endocrinology & Metabolism, 2006
- Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal womenDiabetes, Obesity and Metabolism, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- PRESERVE-βDiabetes Care, 2005
- Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in HumansDiabetes Care, 2003
- Peroxisome Proliferator–Activated Receptor γ and Metabolic DiseaseAnnual Review of Biochemistry, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin SecretionScience, 1995